MedTrace Logo

Alleviation of Alopecia in Breast Cancer Patient Using Synbiotics Formula

NCT06560385 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 40

Last updated 2024-09-19

No results posted yet for this study

Summary

This study aims to explore the efficacy and safety of a synbiotic formula (BLHK03) in alleviating chemotherapy-induced alopecia (CIA) in breast cancer patients and the compositional and functional changes in the gut microbiome of breast cancer patients undergoing chemotherapy and treatment with BLHK03.

Conditions

Interventions

DIETARY_SUPPLEMENT

BLHK03

BLHK03 consists of a blend of probiotics (20 billion CFU in 1 sachet) and prebiotic compounds

DIETARY_SUPPLEMENT

Active placebo

Active placebo contains 5mcg of Vitamin B7

Sponsors & Collaborators

  • GenieBiome Limited

    lead INDUSTRY

Principal Investigators

  • Jessica Ching, PhD · GenieBiome Limited

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-09-11
Primary Completion
2025-08-18
Completion
2026-08-18

Countries

  • Hong Kong

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06560385 on ClinicalTrials.gov